Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list based on their legal acumen and the results they have achieved for their clients in the state.
Mr. Lizza currently serves as lead New Jersey litigation counsel in more than three dozen patent cases for approximately 20 major pharmaceutical companies. This year, Mr. Lizza is representing BioNTech in a case against Moderna in connection with protecting BioNTech’s and Pfizer’s COVID-19 vaccine, the first such inoculation to receive full U.S. Food & Drug Administration approval. Prior examples of his work include representation of Helsinn Healthcare S.A. in major trial victories against Teva and Dr. Reddy’s involving the Aloxi brand drug product (market value of judgments $3.2 billion) and representing Janssen Pharmaceuticals, Inc. (“J&J”) and Mitsubishi Tanabe Pharma Corp. in a complete trial victory against Zydus involving the compound patent covering Janssen’s blockbuster Invokana diabetes drug product, with annual sales in the billions.
In public service, Mr. Lizza currently serves on the Board of Trustees of Saint Peter's University and was honored, along with his wife, Sandra, last May with their Service to Community Award. He has served as Chairman of the Board of Directors of Covenant House New York and as Chairman of the Board of Trustees of Saint Peter's Prep in Jersey City, NJ.
Mr. Lizza's profile notes “Lizza’s practice is particularly suited for New Jersey, as it were, the medicine chest of the world. With more than 40 years of experience, the Saul Ewing partner is also vice chair of the Newark firm’s litigation department. His work involves protecting the IP of branded pharmaceutical companies and medical devices makers, as well as Hatch-Waxman ANDA litigation.”
